Preferred Label : Enadenotucirev;
NCIt synonyms : EnAd; ColoAd1 Oncolytic Virus; Chimeric Oncolytic Adenovirus Ad3/Ad11p Containing Two Deletions in the Viral Genome
in the E3 Region (2444 bp) and in the E4 Region (24 bp) and 197 Non-homologous Nucleotides
in the E2B Region;
NCIt definition : A complex, replication-selective, chimeric adenovirus type 11p (Ad11p)/Ad3 oncolytic
virus vaccine, with potential antineoplastic and immunomodulating activities. Enadenotucirev
has the Ad11p backbone with a large deletion in the E3-region and a small E4-domain
(E4orf4) deleted, in addition to a partial E2B substitution by the Ad3 E2B genes.
Upon intravenous administration of enadenotucirev, the adenovirus selectively reaches
the tumor cells due to the leaky tumor vasculature and replicates in cancer cells;
however, it is unable to replicate in normal, healthy cells. This induces a selective
adenovirus-mediated cytotoxicity in cancer cells, which leads to cancer lysis. Following
the lysis of infected cells, the replicated virus is released and can infect adjacent
cells, which both induces further tumor cell oncolysis and may activate, through the
release of tumor-associated antigens (TAAs) and inflammatory mediators from the lysed
tumor cells, the immune system to mount an anti-tumor immune response. This further
kills tumor cells. This may also stimulate long-term anti-tumor immunity. Although
the cancer-selectivity of enadenotucirev is not entirely understood, the virus does
not efficiently infect normal cells.;
UNII : KX7ZYR6OQW;
CAS number : 1402042-02-7;
Molecule name : ColoAd-1;
NCI Metathesaurus CUI : CL471767;
Origin ID : C113786;
UMLS CUI : C3827142;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
